TheraRadar
Data updated: Jun 28, 2026

NOCDURNA (desmopressin acetate) · FERRING PHARMS INC

Rare Disease Approved 2018-06-21

NOCDURNA is FDA-approved to treat 5 conditions (same as DDAVP).

Source: FDA Label
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
8
Years on Market

Details

Status
Discontinued
First Approved
2018-06-21
Patent Cliff
2030

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
SUBLINGUAL
Dosage Forms
TABLET

Companies

FERRING PHARMS INC
Active Ingredient: DESMOPRESSIN ACETATE

NOCDURNA Approval History

2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2018 to 2018
Jun 2018 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer
FDA Letter Label

What NOCDURNA Treats

5 indications

NOCDURNA is approved for 5 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Central Diabetes Insipidus
  • Polyuria
  • Polydipsia
  • Hemophilia A
  • von Willebrand's Disease

Same approved indications as DDAVP (same active ingredient).

Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NOCDURNA FDA Label Details

Indications & Usage

FDA Label (PDF)

NOCDURNA is FDA-approved to treat 5 conditions — same approved indications as DDAVP.

View full patent landscape →
4 OB patents · 3 families · 116 international docs across 19 countries

NOCDURNA Patents & Exclusivity

Latest Patent: Apr 2030

Patents (4 active)

US9974826 Expires Apr 13, 2030
US11963995 Expires May 21, 2029
US10137167 Expires May 21, 2029
US11020448 Expires May 21, 2029
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for NOCDURNA

Revenue Insights

  • • Quarterly revenue tracking
  • • Historical trend analysis

Patent Timeline

  • • Cliff: 2030
  • • 12 active patents

Trial Analysis

  • • Clinical trial tracking
  • • Development stage analysis

Competitive Landscape

  • • Competitor tracking
  • • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

FDA Approval: NDA022517 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.